Core Laboratories Inc. /DE/ — Form 8-K
Filed July 29, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 38/100
What the filing says
Core Laboratories reported Q2 2026 revenue of $124.6M (up 2% QoQ, down 4% YoY) and GAAP EPS of $0.13 (up 85% QoQ, down 42% YoY). Reservoir Description revenue fell to $78.7M (down 4% QoQ, down 9% YoY) due to Middle East conflicts and Russia-Ukraine impacts; Production Enhancement grew to $45.9M (up 15% QoQ, up 5% YoY). The company repurchased 214,712 shares for $2.7M and declared a $0.01/share Q3 dividend. Free cash flow was $3.1M, and net debt decreased $0.5M to $93.6M (leverage 1.30x).
Why this rating
Q2 results show mixed performance—Production Enhancement strength offset by Reservoir Description decline from geopolitical disruptions (Middle East, Russia-Ukraine). Revenue down 4% YoY and margins compressed. Company is small ($499M market cap); while operational headwinds are real, they appear temporary/external. Modest shareholder returns ($2.7M buyback, $0.01 dividend) and stable balance sheet limit downside. Guidance suggests modest Q3 improvement.
See more from July 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.